A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
NCT06428019
This study is recruiting at 31 US sites in 22 states, according to its ClinicalTrials.gov record last updated .
Summary
Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess the safety of venetoclax in combination with obinutuzumab or acalabrutinib in the treatment of CLL. Adverse events and change in disease activity will be assessed. Venetoclax in combination with obinutuzumab or acalabrutinib is being investigated in the treatment of CLL. Study doctors put the participants in 1 of 4 groups, called treatment arms.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Chronic Lymphocytic Leukemia
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- AbbVie
- Last updated on ClinicalTrials.gov
- April 9, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 2
- Arizona Oncology - Tucson - Rudasill /ID# 267552 · Tucson, AZ
- Southern VA Health Care System /ID# 266254 · Tucson, AZ
California · 2
- UCSF FRESNO/Community Cancer Institute /ID# 270874 · Clovis, CA
- Valkyrie Clinical Trials /ID# 268151 · Los Angeles, CA
Colorado · 1
- Rocky Mountain Cancer Centers - Aurora /ID# 267549 · Aurora, CO
Connecticut · 1
- Yale University School of Medicine /ID# 266224 · New Haven, CT
Florida · 4
- Malcolm Randall V.A. Medical Center /ID# 267825 · Gainesville, FL
- Cancer Specialists of North Florida - Jacksonville - AC Skinner Parkway /ID# 266713 · Jacksonville, FL
- Mid Florida Hematology And Oncology Center /ID# 269159 · Orange City, FL
- Comprehensive Hematology Oncology /ID# 267644 · St. Petersburg, FL
Illinois · 1
- Springfield Clinic - First /ID# 270145 · Springfield, IL
Indiana · 1
- Northwest Cancer Center - Dyer Clinic /ID# 268478 · Dyer, IN
Iowa · 1
- University of Iowa Health Care /ID# 267206 · Des Moines, IA
Maryland · 2
- Center for Cancer and Blood Disorders-American Oncology Partners of Maryland /ID# 266445 · Bethesda, MD
- Maryland Oncology Hematology - Silver Spring /ID# 267557 · Silver Spring, MD
Massachusetts · 1
- UMass Memorial Medical Center /ID# 270023 · Worcester, MA
Michigan · 1
- Henry Ford Hospital /ID# 270973 · Detroit, MI
Missouri · 1
- Saint Lukes Hospital of Kansas City /ID# 267270 · Kansas City, MO
New York · 1
- Icahn School of Medicine at Mount Sinai /ID# 266328 · New York, NY
North Carolina · 2
- Atrium Health /ID# 267219 · Charlotte, NC
- Atrium Health Wake Forest Baptist Medical Center /ID# 273142 · Winston-Salem, NC
Ohio · 1
- Cleveland Clinic Main Campus /ID# 271292 · Cleveland, OH
Oklahoma · 1
- Oklahoma Cancer Specialists and Research Institute /ID# 267643 · Tulsa, OK
Oregon · 1
- Willamette Valley Cancer Institute and Research Center /ID# 266326 · Eugene, OR
Rhode Island · 1
- Lifespan Cancer Institute - Providence /ID# 266550 · Providence, RI
Texas · 2
- Texas Oncology - Austin Midtown /ID# 268152 · Austin, TX
- University of Texas - Southwestern Medical Center /ID# 266528 · Dallas, TX
Virginia · 1
- Virginia Cancer Specialists - Fairfax /ID# 268155 · Fairfax, VA
Washington · 2
- Vista Oncology - East Olympia /ID# 267337 · Olympia, WA
- Northwest Medical Specialties Tacoma /ID# 266327 · Tacoma, WA
West Virginia · 1
- West Virginia University School of Medicine /ID# 267645 · Morgantown, WV
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.